IJSRP, Volume 4, Issue 12, December 2014 Edition [ISSN 2250-3153]
I. Sadaoui, V. Barrès, H. Amrani Hassani Joutei , N. El Gnaoui , W. Mahfoud, H. Benomar and S. Nadifi
Abstract:
The progression of normal prostatic epithelium to androgen-dependent cancer and, eventually, castrate-resistant prostate cancer is a complex process involving many different growth regulatory signals. Activation of epidermal growth factor receptor (EGFR) has been implicated in prostate cancer cell growth.
I. Sadaoui, V. Barrès, H. Amrani Hassani Joutei , N. El Gnaoui , W. Mahfoud, H. Benomar and S. Nadifi (2018); Prostate Adenocarcinoma: are EGFR-targeted drugs of therapeutic relevance for castrate-resistant patients?;
Int J Sci Res Publ 4(12) (ISSN: 2250-3153). http://www.ijsrp.org/research-paper-1214.php?rp=P363524
